一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Therapeutics and Clinical Risk Management >>article
Therapeutics and Clinical Risk Management

Therapeutics and Clinical Risk Management

IF: 2.79
Download PDF

Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice.

Published:4 October 2018 DOI: 10.2147/TCRM.S145779 PMID: 30323610
Nevena Skroza, Nicoletta Bernardini, Ilaria Proietti, Concetta Potenza

Abstract

Actinic keratoses (AKs) are epidermal cutaneous neoplasia observed predominantly in middle-aged and older subjects with mainly photo type I and photo type II on sun-exposed surfaces as a result of DNA damage. AKs have historically been characterized as being "precancerous"; however, now it is considered by many authors a carcinoma in situ that can persist or progress to invasive squamous cell carcinoma (SCC) with metastatic potential. Despite the advances in the recognition of typical clinic, dermoscopic and histologic patterns, currently it is not yet possible to predict which AKs will progress to SCC. For this reason, early diagnosis and effective therapy are recommended based on cost/risk/benefit analysis. Current treatment consists of lesion-directed or field-directed therapies or a combination of both. Among the topical field therapies, ingenol mebutate stands out for its therapeutic efficacy, both as directed lesion therapy and as field directed therapy. The aim of this review is to demonstrate the utility of ingenol mebutate in the management of AK in daily clinical practice and to highlight data from real world in order to confirm evidence from pivotal studies. In order to explore clinical data from real world, PubMed searches were performed with the search terms "clinical data ingenol mebutate" and "real world ingenol mebutate". The hits were examined for relevant articles using defaults criteria. The timeframe for the sample search started from the first publication on this topic in 2008 up to now. A total of 23 articles were found using the keywords specified above. The overview points out a low number of real-life studies on the effectiveness and tolerability of this novel treatment due to short period of clinical experience for its recent approval. Further real-life studies are required in order to better identify the efficacy, safety and adherence of the drug on a larger population.

Substances (1)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Ingenol mebutate 75567-37-2 C25H34O6 182 suppliers $46.00-$2750.00

Similar articles

IF:2.6

Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects*

Anais brasileiros de dermatologia Maria Isabel Ramos Saraiva , Larissa Karine Leite Portocarrero ,etc Published: 1 July 2018
IF:5.9

Creatinine: From physiology to clinical application

European Journal of Internal Medicine Kianoush Kashani , Mitchell H. Rosner ,etc Published: 1 February 2020
徐闻县| 南充市| 汉寿县| 河源市| 商河县| 新绛县| 左云县| 房产| 鸡泽县| 望江县| 准格尔旗| 紫金县| 齐齐哈尔市| 弥勒县| 宜州市| 丰镇市| 科尔| 永德县| 嘉祥县| 仪征市| 徐闻县| 石首市| 邵武市| 嘉兴市| 长顺县| 荣昌县| 吉林省| 章丘市| 鄯善县| 湖州市| 曲阜市| 商都县| 铜陵市| 华宁县| 元谋县| 鲜城| 五原县| 高邮市| 鞍山市| 通州市| 平度市|